NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas

Journal of Clinical Pathology

Volumn 67, Issue 9, 2014, Pages 768-771

  Asch Kendrick, Rebecca J ^a   Samols, Mark A ^a   Lilo, Mohammed T ^a   Subhawong, Andrea P ^a   Sharma, Rajni ^a   Illei, Peter B ^a   Argani, Pedram ^a   Cimino Mathews, Ashley ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; AR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; NKX3-1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BREAST CARCINOMA; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MIDDLE AGED; ONCOGENE NEU; PRIORITY JOURNAL; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; LUNG CARCINOMA; PAGET NIPPLE DISEASE; PATHOLOGY; SECONDARY; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84921974849     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202272     Document Type: Article

References (26)

1. Gelmann EP, Bowen C, Bubendorf L. Expression of NKX3.1 in normal and malignant tissues. Prostate 2003;55:111-17. (Pubitemid 36443998)
2. Bowen C, Bubendorf L, Voeller HJ, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000;60:6111-15.
3. Xu LL, Srikantan V, Sesterhenn IA, et al. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol 2000;163:972-9. (Pubitemid 30091673)
4. Abate-Shen C, Shen MM, Gelmann E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 2008;76:717-27. (Pubitemid 352032747)
5. Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007;31:1246-55. (Pubitemid 47207130)
6. Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 2010;34:1097-105.
7. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15. (Pubitemid 34728896)
8. Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with beast carcinoma. Cancer 2005;103:2241-51. (Pubitemid 40686567)
9. Tan PY, Chang CW, Chng KR, et al. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol Cell Biol 2012;32:399-414.
10. Holmes KA, Song JS, Liu XS, et al. Nkx3-1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity. Cancer Res 2008;68:7380-5.
11. Garay JP, Park BH. Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res 2012;2:434-45.
12. Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:djt319.
13. Qu Q, Mao Y, Fei XC, et al. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS ONE 2013;8:e82650.
14. Cimino-Mathews A, Hicks JL, Illei PB, et al. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Hum Pathol 2012;43:1003-11.
15. Thike AA, Yong-Zheng Chong L, Cheok PY, et al. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol 2014;27:352-60.
16. Cimino-Mathews A, Subhawong AP, Illei PB, et al. GATA-3 expression in breast carcinoma: utility in triple negative, sarcomatoid and metastatic carcinomas. Human Pathol 2013;44:1341-9.
17. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. JAMA 2006;295:2492-502. (Pubitemid 43854964)
18. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74. (Pubitemid 39100473)
19. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
20. Ellis IO, Collins L, Ichihara S, et al. Invasive carcinoma of no special type. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds. World Health Organization classification of tumours of the breast. Lyon, France: IARC Press, 2012:34-8.
21. Arpino G, Bardou VJ, Clark GM, et al. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149-56.
22. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41-8. (Pubitemid 41702621)
23. Ferlicot S, Vincent-Salomon A, Medioni J, et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 2004;40:336-41. (Pubitemid 38121269)
24. Dawood S, Hu R, Homes MD, et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2011;126:185-92.
25. Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28:1684-91.
26. Kim HS, Park I, Cho HJ, et al. Analysis of the potent prognostic factors in luminal-type breast cancer. J Breast Cancer 2012;15:401-6.